SCHEMBL3378677

SCHEMBL3378677

Cc1csc2c(=O)n(NC(=O)Cc3cccc(F)c3)c(SC(C)C)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 1/20 0.40
ROCK1 Q13464 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.37
THRB P10828 1/20 0.37
TGM2 P21980 1/20 0.37
GLS O94925 2/20 0.36
RAB9A P51151 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
FPR1 P21462 1/20 0.35
PIK3C2A O00443 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13282917 0.89 RAB9A (0.43) PRKACAROCK1MEN1KMT2AMAPT
SCHEMBL3381133 0.79 RAB9A (0.48) PRKACAROCK1MEN1KMT2AMAPT
SCHEMBL3414928 0.78 NPSR1 (0.45) MEN1KMT2AMAPTL3MBTL1LMNA
SCHEMBL13283007 0.78 RAB9A (0.44) PRKACAROCK1MEN1KMT2AMAPT
SCHEMBL13283141 0.78 RAB9A (0.46) PRKACAROCK1MEN1KMT2AMAPT
SCHEMBL13283000 0.74 NPSR1 (0.44) MEN1KMT2AMAPTLMNATHRB
SCHEMBL13282995 0.73 NPSR1 (0.52) MEN1KMT2ALMNARAB9ANPSR1
SCHEMBL3380682 0.72 NPSR1 (0.56) MEN1KMT2AL3MBTL1LMNARAB9A
SCHEMBL13283002 0.70 RAB9A (0.48) MEN1KMT2AL3MBTL1LMNARAB9A
SCHEMBL13283008 0.70 NPSR1 (0.51) MEN1KMT2AMAPTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585522-B1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN INC (US) 2010-11-17 EP disclosed
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed
EP-1585522-A4 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN INC (US) 2006-08-09 EP disclosed
EP-1585522-A2 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2005-10-19 EP disclosed
US-20040198724-A1 Quinazolinones as potassium channel modulators ICAGEN, INC. 2004-10-07 US disclosed
WO-2004058704-A2 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198724-A1 Quinazolinones as potassium channel modulators KCNQ1, KCNK17, KCNQ2 PRKACA 1569/4885ROCK1 2210/4885MEN1 629/4885
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS KCNQ1, KCNK17, KCNQ2 PRKACA 1569/4885ROCK1 2210/4885MEN1 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.